Daihan Pharmaceutical Co.Ltd (023910) — Free Cash Flow Generation Index
Daihan Pharmaceutical Co.Ltd (023910) has a Free Cash Flow Generation Index of -0.14x as of September 2025. Free cash flow of ₩-1.32 Billion represents 0% of operating cash flow (₩9.47 Billion). See Daihan Pharmaceutical Co.Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Daihan Pharmaceutical Co.Ltd Free Cash Flow Generation Index (2014–2024)
Historical FCF Generation Index trend for Daihan Pharmaceutical Co.Ltd across 11 annual periods. Explore 023910 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year Free Cash Flow Generation Index for Daihan Pharmaceutical Co.Ltd. For the full company profile including market capitalisation, see Daihan Pharmaceutical Co.Ltd (023910) market capitalisation.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.56x | ₩19.84 Billion | ₩35.64 Billion | ₩15.80 Billion | ▲ +23.1% |
| 2023 | 0.45x | ₩17.58 Billion | ₩38.86 Billion | ₩21.28 Billion | ▼ -35.6% |
| 2022 | 0.70x | ₩20.38 Billion | ₩29.00 Billion | ₩8.62 Billion | ▼ -0.8% |
| 2021 | 0.71x | ₩28.77 Billion | ₩40.62 Billion | ₩11.85 Billion | ▼ -15.7% |
| 2020 | 0.84x | ₩28.27 Billion | ₩33.63 Billion | ₩5.36 Billion | ▼ -43.6% |
| 2019 | 1.49x | ₩52.57 Billion | ₩35.26 Billion | ₩17.30 Billion | ▼ -26.9% |
| 2018 | 2.04x | ₩91.63 Billion | ₩44.94 Billion | ₩46.69 Billion | ▲ +0.5% |
| 2017 | 2.03x | ₩41.50 Billion | ₩20.45 Billion | ₩21.05 Billion | ▲ +13.7% |
| 2016 | 1.78x | ₩49.82 Billion | ₩27.92 Billion | ₩21.90 Billion | ▲ +46.2% |
| 2015 | 1.22x | ₩21.94 Billion | ₩17.98 Billion | ₩3.96 Billion | ▼ -42.0% |
| 2014 | 2.10x | ₩19.95 Billion | ₩9.48 Billion | ₩10.47 Billion | — |